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Abstract
Background—Studies have associated thiazolidinedione (TZD) treatment with cardiovascular
disease (CVD) and questioned whether the two available TZDs, rosiglitazone and pioglitazone,
have different CVD risks. We compared CVD incidence, cardiovascular (CV) and all-cause
mortality in type 2 diabetic patients treated with rosiglitazone or pioglitazone as their only TZD.
Methods—We analyzed survey, medical record, administrative, and National Death Index (NDI)
data from 1999 through 2003 from Translating Research Into Action for Diabetes (TRIAD), a
prospective observational study of diabetes care in managed care. Medications, CV procedures,
and CVD were determined from health plan (HP) administrative data, and mortality was from
NDI. Adjusted hazard rates (AHR) were derived from Cox proportional hazard models adjusted
for age, sex, race/ethnicity, income, history of diabetic nephropathy, history of CVD, insulin use,
and HP.
Results—Across TRIAD’s ten HPs, 1,815 patients (24%) filled prescriptions for a TZD, 773
(10%) for only rosiglitazone, 711 (10%) for only pioglitazone, and 331 (4%) for multiple TZDs.
In the seven HPs using both TZDs, 1,159 patients (33%) filled a prescription for a TZD, 564
(16%) for only rosiglitazone, 334 (10%) for only pioglitazone, and 261 (7%) for multiple TZDs.
For all CV events, CV and all-cause mortality, we found no significant difference between
rosiglitazone and pioglitazone.
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Conclusions—In this relatively small, prospective, observational study, we found no
statistically significant differences in CV outcomes for rosiglitazone- compared to pioglitazone-
treated patients. There does not appear to be a pattern of clinically meaningful differences in CV
outcomes for rosiglitazone- versus pioglitazone-treated patients.
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INTRODUCTION
The first thiazolidinedione (TZD), troglitazone, was approved by the Food and Drug
Administration (FDA) in January 1997 and withdrawn from the market in March 2000. The
two available TZDs, rosiglitazone (FDA approved May 1999) and pioglitazone (FDA
approved July 1999) have come under scrutiny because reports of potential adverse
cardiovascular (CV) events and several meta-analyses have suggested differential risks.1-5
The purpose of this study was to compare the risk of adverse CV events and mortality in
patients with type 2 diabetes treated with rosiglitazone or pioglitazone as their only TZD
after adjustment for differences between groups. We used data from Translating Research
Into Action for Diabetes (TRIAD), a large, prospective, observational study of diabetes care
in managed care. In our analyses, we report the full range of outcomes previously reported
in the literature: nonfatal myocardial infarction (MI); coronary revascularization; the
combined outcome of nonfatal MI or coronary revascularization; nonfatal stroke; the
combined outcome of nonfatal MI, coronary revascularization or nonfatal stroke; CV
mortality; all-cause mortality; the combined outcome of nonfatal MI or all-cause mortality;
the combined outcome of nonfatal MI, nonfatal stroke, or CV mortality; the combined
outcome of nonfatal MI, nonfatal stroke, or all-cause mortality; and the combined outcome
of nonfatal MI, coronary revascularization, nonfatal stroke, or all-cause mortality.
METHODS
The TRIAD methodology has been described in detail elsewhere.6 Six research centers
collaborated with ten managed care health plans (HPs) and 68 provider groups that served
approximately 180,000 geographically and ethnically diverse patients with diabetes.
Institutional review boards at each participating center approved the study. All participants
provided informed consent.
TRIAD enrolled 11,927 patients between July 2000 and August 2001. All were at least 18
years old, not pregnant, community-dwelling, English or Spanish speaking, and
continuously enrolled in the HP for at least 18 months prior to the baseline patient survey.
Medical record reviews were performed at baseline, HP administrative data were collected
for 1999 through 2003, and the National Death Index (NDI) was searched for deaths
occurring through 2003. We analyzed data for patients who had type 2 diabetes (excluding
those with age at diagnosis under 30 years and treatment with insulin only) and with
complete data for the variables investigated (N=7,439).
Across TRIAD’s ten HPs, 1,815 patients (24%) filled at least one prescription for a TZD,
773 (10%) for only rosiglitazone, 711 (10%) for only pioglitazone, and 331 (4%) for more
than one TZD. In the seven HPs using both TZDs, 1,159 patients (33%) filled at least one
prescription for a TZD, 564 (16%) for only rosiglitazone, 334 (10%) for only pioglitazone,
and 261 (7%) for more than one TZD (Figure 1). Patients filling prescriptions for more than
one TZD were excluded.
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We used HP administrative data to determine TZD exposure and verify drug benefits.
Patient surveys and medical record reviews were used to determine if patients were treated
with insulin at baseline. Subsequent initiation of insulin was determined from analysis of
administrative data. We ascertained nonfatal acute myocardial infarction, stroke, or
percutaneous or surgical CV intervention from HP administrative data. We used the
following International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) diagnosis codes (with any 4th or 5th digit): 410 (acute myocardial infarction),
431 (intracerebral hemorrhage), 433 (occlusion and stenosis of precerebral arteries), and 434
(occlusion of cerebral arteries). Coronary revascularization procedures included operations
on vessels of the heart (ICD-9-CM procedure code 36 with any 3rd or 4th digit), coronary
artery repair procedures (CPT codes 33500-33572), intracoronary stents, coronary balloon
angioplasty or atherectomy (CPT codes 92980-92984, 92995, 92996). Deaths and cause of
death were ascertained from NDI.7
We performed time-to-event analyses. Our study window started with the first TZD
prescription and ended with an event or censoring. Event dates were the first occurrence of a
CV event or procedure after the first TZD prescription was filled. Patients without CV
events or procedures were censored at whichever occurred first: the date the last TZD
prescription was filled plus the days supply dispensed plus 90 days (to account for any
persistent biological effects of the TZD); the date the person disenrolled from the HP; the
last date of service recorded in the administrative data; or TRIAD’s administrative data cut-
off date. The end of the study window was re-evaluated for each outcome. Because we were
concerned that the use of a random effect in the model might not adequately adjust for
differences in patients across HPs, we conducted analyses after excluding the three HPs that
appeared to have only one TZD on formulary (as evidenced by prescriptions filled for only
one TZD). For patients in these three plans, exposure to a specific TZD could not be
distinguished from other unmeasured characteristics associated with membership in that HP.
We compared groups using 2-tailed t-tests for continuous variables and χ2 tests for
categorical variables. We tested the assumption of proportional hazards with graphical
display and examination of the correlations between the ranked failure time variable and the
Schoenfeld residuals of the independent variables. We used Cox proportional hazard
multivariate models adjusted for baseline age, sex, race/ethnicity, income, history of diabetic
nephropathy, history of CVD (transient ischemic attack, cerebrovascular accident, angina
pectoris, myocardial infarction, coronary heart disease, congestive heart failure, or
peripheral vascular disease), insulin use, and HP. Missing values for age, sex, race/ethnicity,
income, and smoking were relatively infrequent (< 15% in all cases) and were imputed using
single imputation with the transcan function in S-PLUS (edition 6.1; Insightful, Seattle,
WA). Patients’ missing values for other variables used in this study were excluded.
Statistical analyses were performed using SAS (version 9.1.3, SAS Institute, Cary, NC).
RESULTS
The first prescription for rosiglitazone was filled in June 1999 and the first prescription for
pioglitazone was filled in August 1999. Subsequent uptake of TZD therapy was rapid. The
cumulative number of patients with prescriptions for rosiglitazone was approximately 500,
970, 1,250, and 1,400 at one, two, three and four years after the first prescription was filled.
For pioglitazone, the cumulative number of patients filling prescriptions was approximately
500, 800, 1,080, and 1,300 at one, two, three and four years.
The TRIAD HPs were ethnically, socio-economically, and geographically diverse. Among
the ten HPs, seven had substantial numbers of prescriptions filled for both rosiglitazone and
pioglitazone. In two other HPs, pioglitazone accounted for over 99% of TZD prescriptions
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and in one HP, rosiglitazone accounted for 100% of TZD prescriptions. Patients in the latter
3 HPs differed from each other with respect to demographic characteristics and
socioeconomic position, and the differences in the characteristics of rosiglitazone-treated
patients and pioglitazone-treated patients were greater when all ten HPs were included in the
analyses. Limiting the analyses to the seven HPs with substantial numbers of patients filling
prescriptions for both TZDs reduced the differences between rosiglitazone- and
pioglitazone-treated patients. (Table 1).
In general, rosiglitazone-treated patients were younger, more likely to be female, black and
lower income than pioglitazone-treated patients. Rosiglitazone patients were less likely to
have a history of diabetic nephropathy but were more likely to be insulin treated than
pioglitazone-treated patients.
Table 2 shows the distribution of CV procedures, adverse CV events, and mortality by
treatment group. The observed, unadjusted event rates were similar across treatment groups.
Figure 2 shows the adjusted hazard ratios (AHR) for CV procedures, adverse CV events,
and mortality for rosiglitazone-treated patients compared to pioglitazone-treated patients
after adjusting for age, sex, race/ethnicity, income, history of diabetic nephropathy, history
of CVD, insulin use, and HP. Because of potential bias, we performed a sub-analysis
excluding patients who filled TZD prescriptions before the baseline survey. We repeated the
analyses for all outcomes and there were no differences in the results (not shown). For all
CV events, CV and all-cause mortality, we found no statistically significant difference
between rosiglitazone-treated patients and pioglitazone-treated patients.
DISCUSSION
In this relatively small, prospective, observational study of diabetes care in managed care,
we found that CV risk was similar for patients with type 2 diabetes treated with rosiglitazone
and pioglitazone and observed no pattern of differential risk.
Previous studies that have directly compared rosiglitazone- to pioglitazone-treated patients
have not found consistent, clinically meaningful differences in CV outcomes, except for a
trend favoring pioglitazone treatment to rosiglitazone treatment with respect to all-cause
mortality. Table 3 summarizes the published literature. A rosiglitazone-to-pioglitazone
comparison conducted in 2007 by the manufacturer of pioglitazone focused on acute
myocardial infarction after initiating TZD treatment and reported that pioglitazone-treated
patients had a reduced risk of hospitalization for myocardial infarction (AHR 0.78, 95% CI
0.63-0.96) and for the composite outcome of nonfatal myocardial infarction and coronary
revascularization (AHR 0.85, 95% CI 0.75-0.98).8 This retrospective observational analysis
relied on administrative claims data, which reduced the investigators’ ability to adjust for
potential confounders. A 2007 study of elderly patients (mean age 75 years) using a nested
case-control methodology showed worse outcomes for patients treated with rosiglitazone
with respect to acute myocardial infarction and all-cause mortality.9 However, the study was
not powered to directly compare rosiglitazone- to pioglitazone-treated patients, and indeed,
compared rosiglitazone- and pioglitazone-treated patients to patient treated with other oral
antidiabetic medications. In addition, patients receiving insulin were excluded from the
analysis. A 2008 study that compared rosiglitazone- and pioglitazone-treated Medicare
beneficiaries also relied on claims and enrollment data, and found reduced risk of all-cause
mortality for the pioglitazone-treated patients (AHR 0.87, 95% CI 0.79-0.95), but no
difference with respect to myocardial infarction or stroke.10 A recent retrospective study of
patients using oral anti-diabetic agents that excluded patients using insulin or multiple oral
anti-diabetic agents found no significant difference between rosiglitazone and pioglitazone
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for the composite outcome of myocardial infarction or coronary revascularization or for all-
cause mortality.11 Another recent study comparing rosiglitazone to pioglitazone treatment
drew subjects from a single HMO treated within a single health system, included time-
varying medication use and adjusted for propensity to treat based on medication history and
clinical function, and estimated household income from the census.12 It found that
pioglitazone treatment was associated with a reduction in all-cause mortality (AHR 0.60,
95% CI 0.42-0.96) compared to rosiglitazone treatment but found no significant differences
with respect to acute myocardial infarction or stroke.12 A 2009 study of patients 66 years of
age and older compared those initiating rosiglitazone and pioglitazone and found no
significant difference in the risk of acute myocardial infarction. The CV mortality outcome
in this study included heart failure and was therefore not directly comparable to ours. The
study found that pioglitazone-treated patients had lower risk of all-cause mortality than
rosiglitazone-treated patients (AHR 0.86, 95% CI 0.75-0.98). Besides excluding younger
patients, this study excluded patients receiving insulin and included residents of long-term
care facilities.13
Our analyses directly compared rosiglitazone-treated patients to pioglitazone-treated
patients. All were patients with type 2 diabetes enrolled in TRIAD’s managed care HPs and
were geographically, ethnically, and socioeconomically diverse. We included younger
patients and those treated with insulin and/or other oral anti-diabetic agents. We used
multiple sources of data including survey responses, medical record reviews, administrative
data, and NDI. We performed time-to-event analyses and adjusted for potential confounders
and reported the full range of outcomes previously reported in the literature. Data collection
was completed before publication of any reports of the favorable or unfavorable impact of
TZDs on CV events which might have impacted prescribing patterns.
Despite these strengths, our analyses had several limitations. First, if a patient’s HP
coverage included a limit on pharmacy benefits, patients may have filled prescriptions that
we did not detect. We expect this potential problem to be minor because two large HPs
submitted pharmacy utilization, not just claims, capturing prescriptions that were not
covered. In addition, most HPs included denied claims, further capturing prescriptions that
were not covered. Second, TRIAD participants showed a wide range of length of TZD
exposure and number of TZDs used, potentially confounding the results. We mitigated this
risk by excluding patients who used multiple TZDs. Third, using a model with a random
effect for HP might not adequately adjust for differences in TZD prescribing patterns and
population characteristics across HPs. We addressed this potential bias by performing sub-
analyses limited to HPs with substantial numbers of prescriptions of both rosiglitazone and
pioglitazone. Fourth, it is possible that those with a recent CV event were less likely to
participate in TRIAD; however, this is unlikely to cause a bias in rosiglitazone vs.
pioglitazone treatment. Finally, we acknowledge that our sample size was relatively small.
We estimate that we had 80% power to detect a 5% difference in absolute risk between
treatment groups. Our overall event rates of 7-9% were, however, much higher than the
event rate of < 1% reported in the meta-analysis by Nissen and Wolski.1 As recently
suggested by Hennekens and DeMets, the meta-analysis may be most useful for hypothesis
generation. Value of meta-analyses is dependent on the quality and comparability of the data
analyzed, and large and long-term, prospective randomized controlled clinical trials will be
needed to conclusively demonstrate small to moderate harm.14
In conclusion, in this relatively small, prospective, observational study, we found no
statistically significant differences in CV risk for rosiglitazone- compared to pioglitazone-
treated patients. There did not appear to be clinically meaningful pattern of differences in
CV outcomes for rosiglitazone- versus pioglitazone-treated patients.
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KEY POINTS
• In this relatively small, prospective, observational study, we found no
statistically significant differences in cardiovascular risk for rosiglitazone-
compared to pioglitazone-treated patients.
• There does not appear to be a pattern of clinically meaningful differences in
cardiovascular outcomes for rosiglitazone- versus pioglitazone-treated patients.
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Figure 1. Study Population
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Figure 2. Adjusted* Hazard Ratios among Patients with Type 2 Diabetes Treated with
Rosiglitazone or Pioglitazone, TRIAD 1999-2003
*Adjusted for age, sex, race/ethnicity, income, history of diabetic nephropathy, history of
cardiovascular disease (transient ischemic attack, cerebrovascular accident, angina pectoris,
myocardial infarction, congestive heart failure, coronary heart disease, peripheral vascular
disease), insulin use, and health plan.
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